iCo Therapeutics (TSX-V: ICO, Vancouver, Canada) has announced the execution of a licensing deal with Immune Pharmaceuticals (Ness-Ziona, Israel) for Bertilimumab (iCo-008) for systemic uses. iCo-008, also known as Bertilimumab or CAT-213, is a human monoclonal antibody (mAb) targeting eotaxin-1, a chemo- attractant for eosinophils and a ligand for chemokine receptor 3 (CCR3). The mAb was originally licensed by iCo Therapeutics from AstraZeneca/MedImmune and has already undergone clinical trial evaluation in a severe allergy indication. There are currently plans to conduct exploratory studies for the mAb in wet AMD and a possible phase 2 study in severe ocular allergies (vernal & atopic keratoconjunctivitis).